堡垒生物科技公司 （Fortress Biotech, Inc.）（纳斯达克代码：FBIO）周一宣布，Sentynl Therapeutics, Inc.已向美国食品药品监督管理局重新提交了CUTX-101的新药申请（NDA），该药物是一种用于治疗儿科门克斯病患者的铜组氨酸制剂。这一更新信息在基于最近一份SEC文件的新闻稿中披露。

XI'AN, Nov. 12 (Xinhua) -- A comprehensive six-year archaeological survey in northwest China's Shaanxi Province has found 573 ancient stone fortress settlements, dating from the prehistoric era to the ...